Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: What Links Actimmune And Vertex’s Event Horizon?

Executive Summary

Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with.

Advertisement

Related Content

Stockwatch: Pandora’s Interim Analysis
Stockwatch: Earnings Move From Mediocre to Worse
InterMune clinches $55m deal to offload waning Actimmune
Problems with risk-sharing study must not deter future collaborations

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097847

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel